Record Details

A single-center non-blinded randomized clinical trial to assess the safety and effectiveness of PhR160 spray in the treatment of COVID-19 pneumonia

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title A single-center non-blinded randomized clinical trial to assess the safety and effectiveness of PhR160 spray in the treatment of COVID-19 pneumonia
 
Creator Roshandel, H R Sheikh
Mirkazemi, R
Ahmadabadi, H R
Memarzadeh, M R
Zahedifard, N
Saffari, M
Jazani, M
Rahmani, M
Hosseini, M
Raei, M
Sharifi, AR
Ghadimi, F
Ameli, P
Valinejad, M
Mohtashami, R
 
Subject COVID-19
Hospitalized patients
Iranian Traditional Medicine
Pinen-Hydronoplacton-Ribonucleic acid (PHR160)
 
Description 7-16
COVID-19 is an emerging pandemic that caused a very widespread infection with more than 1000000 cases in Iran within a year. The main cause of mortality among patients with COVID-19 is pulmonary failure. In Iranian Traditional Medicine, essences have been used for curing pulmonary diseases. Pinen-Hydronoplacton-Ribonucleic acid (PHR) is an inhaler spray made of seven different plants, which all are used by humans and have desirable pharmacological features for treating pulmonary symptoms of COVID-19 patients. This study was conducted to assess the safety and effectiveness of PHR160 spray in improving pulmonary symptoms of COVID-19 patients. This was a single-centre, non-blinded randomized clinical trial with two parallel groups in two different wards of Baqiyatallah hospital, Tehran, Iran. Participants were 63 male patients diagnosed with COVID-19 pneumonia, divided into 2 groups of 32 in the intervention group and 31 in the control group. The intervention group received 5 days of PHR160 spray, 10 puffs each day, 300 micrograms in each puff in addition to the routine treatment. Oxygen saturation was measured by a pulse oximeter, every six hours and recorded daily. This study showed that administration of PhR 160 in patients of COVID-19 was safe, and it significantly increased the arterial oxygen saturation percentage in COVID-19 patients. In addition, it decreased hospitalization duration, dyspnea score, and cough score significantly in the patients. The statistical modelling test, with adjusting the age and respiratory rate for baseline and 4 days of the intervention, shows that the oxygen saturation percentage mean was significantly more in the intervention group by 5.14 units (p
 
Date 2022-02-15T10:22:03Z
2022-02-15T10:22:03Z
2022-01
 
Type Article
 
Identifier 0975-1068 (Online); 0972-5938 (Print)
http://nopr.niscair.res.in/handle/123456789/59180
 
Language en
 
Relation Int. Cl.22: A61K 9/72, A61K 31/00, A61K 36/00, A61K 45/00
 
Publisher CSIR-NIScPR
 
Source IJTK Vol.21(1) [January 2022]